Arrowstreet Capital Limited Partnership Sells 67,298 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Arrowstreet Capital Limited Partnership lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 64.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,387 shares of the medical equipment provider's stock after selling 67,298 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.05% of Lantheus worth $3,255,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. State of New Jersey Common Pension Fund D lifted its position in shares of Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after purchasing an additional 115 shares during the last quarter. Bleakley Financial Group LLC lifted its holdings in Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after buying an additional 129 shares during the last quarter. Avantax Advisory Services Inc. grew its position in shares of Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after acquiring an additional 132 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after acquiring an additional 134 shares during the last quarter. Finally, Aurora Investment Counsel lifted its stake in Lantheus by 0.8% during the fourth quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock worth $1,718,000 after purchasing an additional 146 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $0.61 during mid-day trading on Monday, reaching $101.39. 77,832 shares of the company traded hands, compared to its average volume of 952,822. The stock has a fifty day simple moving average of $94.00 and a 200-day simple moving average of $95.56. The firm has a market cap of $6.94 billion, a PE ratio of 16.83 and a beta of 0.20. Lantheus Holdings, Inc. has a fifty-two week low of $59.56 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock valued at $6,110,806 over the last three months. Insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on LNTH. B. Riley dropped their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. JMP Securities restated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.